LifeMD Partners with Antares Pharma for Direct-to-Patient Testosterone Therapy Program — LifeMD, Inc.

Event summary

LifeMD and Antares Pharma (a Halozyme subsidiary) launched an exclusive co-marketing collaboration for XYOSTED, a testosterone therapy program, set to debut in July 2026 across 37 states.
The program offers virtual consultations, lab testing, and home delivery of XYOSTED at a fixed price of $249 per month, targeting untreated hypogonadism patients.
LifeMD will handle telehealth evaluations and pharmacy services, while Antares Pharma provides the FDA-approved testosterone auto-injector.
The collaboration aims to expand awareness of testosterone deficiency and streamline access to treatment through a transparent pricing model.

The big picture

This collaboration marks a strategic shift in how virtual care platforms partner with pharmaceutical manufacturers to improve access to specialized treatments. By integrating telehealth, diagnostics, and home delivery into a single service, LifeMD and Antares Pharma are addressing key barriers in testosterone deficiency treatment—a fragmented market where many patients remain undiagnosed or untreated due to cost and convenience issues.

What we're watching

Market Expansion: Whether LifeMD can successfully expand the program to additional states and integrate insurance coverage beyond self-pay options.
Regulatory Compliance: The pace at which telehealth prescribing regulations for controlled substances evolve, impacting program availability.
Patient Adoption: How the transparent pricing model and convenience of home delivery influence patient uptake and long-term retention.